A review of excision repair cross-complementation group 1 in colorectal cancer

Clinical Colorectal Cancer

Volumn 10, Issue 3, 2011, Pages 157-164

  Bohanes, Pierre ^a   Labonte, Melissa J ^a   Lenz, Heinz Josef ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Colorectal cancer; ERCC1; Oxaliplatin; Predictive; Prognostic

Indexed keywords

1,2 DIAMINOCYCLOHEXANE; CAPECITABINE; CARBOPLATIN; CISPLATIN; CYCLOBUTANE; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FLUOROURACIL; IRINOTECAN; MESSENGER RNA; OXALIPLATIN; VASCULOTROPIN RECEPTOR;

ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; COLORECTAL CANCER; CYTOTOXICITY; DISEASE COURSE; DRUG EFFICACY; DRUG SENSITIVITY; DRUG STRUCTURE; GENE EXPRESSION; GENOTYPE; HUMAN; IMMUNOHISTOCHEMISTRY; NEUROPATHY; OVERALL SURVIVAL; PREDICTIVE VALUE; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL RATE; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 80052469770     PISSN: 15330028     EISSN: 19380674     Source Type: Journal    
DOI: 10.1016/j.clcc.2011.03.024     Document Type: Article

References (41)

1. T. André, C. Boni, and M. Navarro Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial J Clin Oncol 27 2009 3109 3116
2. J.P. Kuebler, H.S. Wieand, and M.J. O'Connell Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07 J Clin Oncol 25 2007 2198 2204 (Pubitemid 46954643)
3. A. de Gramont, A. Figer, and M. Seymour Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer J Clin Oncol 18 2000 2938 2947 (Pubitemid 30644117)
4. J.H. Hoeijmakers Genome maintenance mechanisms for preventing cancer Nature 411 2001 366 374 (Pubitemid 32467046)
5. S. Usanova, A. Piée-Staffa, and U. Sied Cisplatin sensitivity of testis tumour cells is due to deficiency in interstrand-crosslink repair and low ERCC1-XPF expression Mol Cancer 9 2010 248
6. O.V. Tsodikov, J.H. Enzlin, and O.D. Schrer Crystal structure and DNA binding functions of ERCC1, a subunit of the DNA structure-specific endonuclease XPF-ERCC1 Proc Natl Acad Sci USA 102 2005 11236 11241 (Pubitemid 41153804)
7. U. Vogel, M. Dybdahl, and G. Frentz DNA repair capacity: inconsistency between effect of over-expression of five NER genes and the correlation to mRNA levels in primary lymphocytes Mutat Res 461 2000 197 210
8. C. Welsh, R. Day, and C. McGurk Reduced levels of XPA, ERCC1 and XPF DNA repair proteins in testis tumor cell lines Int J Cancer 110 2004 352 361 (Pubitemid 38649885)
9. K.V. Ferry, T.C. Hamilton, and S.W. Johnson Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells: role of ERCC1-XPF Biochem Pharmacol 60 2000 1305 1313
10. S. Hector, W. Bolanowska-Higdon, and J. Zdanowicz In vitro studies on the mechanisms of oxaliplatin resistance Cancer Chemother Pharmacol 48 2001 398 406 (Pubitemid 33027997)
11. M. Selvakumaran, D.A. Pisarcik, and R. Bao Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines Cancer Res 63 2003 1311 1316 (Pubitemid 36348710)
12. C.K. Youn, M.H. Kim, and H.J. Cho Oncogenic H-Ras up-regulates expression of ERCC1 to protect cells from platinum-based anticancer agents Cancer Res 64 2004 4849 4857
13. S. Arnould, I. Hennebelle, and P. Canal Cellular determinants of oxaliplatin sensitivity in colon cancer cell lines Eur J Cancer 39 2003 112 119 (Pubitemid 36005433)
14. J. Boyer, E.G. McLean, and S. Aroori Characterization of p53 wild-type and null isogenic colorectal cancer cell lines resistant to 5-fluorouracil, oxaliplatin, and irinotecan Clin Cancer Res 10 2004 2158 2167 (Pubitemid 38375578)
15. J.J. Yu, K.B. Lee, and C. Mu Comparison of two human ovarian carcinoma cell lines (A2780/CP70 and MCAS) that are equally resistant to platinum, but differ at codon 118 of the ERCC1 gene Int J Oncol 16 2000 555 560
16. D.J. Park, J. Stoehlmacher, and W. Zhang ERCC1 polymorphism is associated with differential ERCC1 gene expression Proc Am Assoc Cancer Res 43 2002 321 (abstract 1591)
17. P.M. Chang, C.H. Tzeng, and P.M. Chen ERCC1 codon 118 C→T polymorphism associated with ERCC1 expression and outcome of FOLFOX-4 treatment in Asian patients with metastatic colorectal carcinoma Cancer Sci 100 2009 278 283
18. D. Atkins, K.A. Reiffen, and C.L. Tegtmeier Immunohistochemical detection of EGFR in paraffin-embedded tumor tissues: variation in staining intensity due to choice of fixative and storage time of tissue sections J Histochem Cytochem 52 2004 893 901 (Pubitemid 38857154)
19. J. Murphy, and S.A. Bustin Reliability of real-time reverse-transcription PCR in clinical diagnostics: gold standard or substandard? Expert Rev Mol Diagn 9 2009 187 197
20. J. Viguier, V. Boige, and C. Miquel ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer Clin Cancer Res 11 2005 6212 6217 (Pubitemid 41262950)
21. Y. Shirota, J. Stoehlmacher, and J. Brabender ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy J Clin Oncol 19 2001 4298 4304 (Pubitemid 33096777)
22. K. Uchida, P.V. Danenberg, and K.D. Danenberg Thymidylate synthase, dihydropyrimidine dehydrogenase, ERCC1, and thymidine phosphorylase gene expression in primary and metastatic gastrointestinal adenocarcinoma tissue in patients treated on a phase I trial of oxaliplatin and capecitabine BMC Cancer 8 2008 386
23. H.J. Lenz, W. Zhang, and M.M. Shi ERCC-1 gene expression levels and outcome to FOLFOX chemotherapy in patients enrolled in CONFIRM1 and CONFIRM2 J Clin Oncol 2008 abstract 1431
24. S.H. Kim, H.C. Kwon, and S.Y. Oh Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer Am J Clin Oncol 32 2009 38 43
25. M.S. Braun, S.D. Richman, and P. Quirke Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial J Clin Oncol 26 2008 2690 2698
26. L. Paré, E. Marcuello, and A. Altés Pharmacogenetic prediction of clinical outcome in advanced colorectal cancer patients receiving oxaliplatin/5-fluorouracil as first-line chemotherapy Br J Cancer 99 2008 1050 1055
27. E. Martinez-Balibrea, A. Abad, and E. Aranda Pharmacogenetic approach for capecitabine or 5-fluorouracil selection to be combined with oxaliplatin as first-line chemotherapy in advanced colorectal cancer Eur J Cancer 44 2008 1229 1237
28. J. Stoehlmacher, D.J. Park, and W. Zhang A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer Br J Cancer 91 2004 344 354 (Pubitemid 39037082)
29. Y.C. Chen, C.H. Tzeng, and P.M. Chen Influence of GSTP1 I105V polymorphism on cumulative neuropathy and outcome of FOLFOX-4 treatment in Asian patients with colorectal carcinoma Cancer Sci 101 2010 530 535
30. A. Ruzzo, F. Graziano, and F. Loupakis Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy J Clin Oncol 25 2007 1247 1254 (Pubitemid 46640571)
31. J. Liang, T. Jiang, and R.Y. Yao The combination of ERCC1 and XRCC1 gene polymorphisms better predicts clinical outcome to oxaliplatin-based chemotherapy in metastatic colorectal cancer Cancer Chemother Pharmacol 66 2010 493 500
32. W. Chua, D. Goldstein, and C.K. Lee Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer Br J Cancer 101 2009 998 1004
33. K.L. Spindler, R.F. Andersen, and L.H. Jensen EGF61A>G polymorphism as predictive marker of clinical outcome to first-line capecitabine and oxaliplatin in metastatic colorectal cancer Ann Oncol 21 2010 535 539
34. M.C. Etienne-Grimaldi, G. Milano, and F. Maindrault-Goebel Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and FOLFOX response in colorectal cancer patients Br J Clin Pharmacol 69 2010 58 66
35. H. Kobayashi, K. Sugihara, and H. Uetake Messenger RNA expression of TS and ERCC1 in colorectal cancer and matched liver metastasis Int J Oncol 33 2008 1257 1262
36. C.H. Köhne, D. Cunningham, and C.F. Di Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients Ann Oncol 13 2002 308 317 (Pubitemid 34704985)
37. M.L. Slattery, K. Curtin, and R.K. Wolff A comparison of colon and rectal somatic DNA alterations Dis Colon Rectum 52 2009 1304 1311
38. S.C. Larsson, and A. Wolk Obesity and colon and rectal cancer risk: a meta-analysis of prospective studies Am J Clin Nutr 86 2007 556 565 (Pubitemid 47435820)
39. C. Massacesi, B. Pistilli, and M. Valeri Predictors of short-term survival and progression to chemotherapy in patients with advanced colorectal cancer treated with 5-fluorouracil-based regimens Am J Clin Oncol 25 2002 140 148 (Pubitemid 34293066)
40. G. Schwartsmann, M.J. Ratain, and G.M. Cragg Anticancer drug discovery and development throughout the world J Clin Oncol 20 2002 47S 59S
41. V. Moreno, F. Gemignani, and S. Landi Polymorphisms in genes of nucleotide and base excision repair: risk and prognosis of colorectal cancer Clin Cancer Res 12 2006 2101 2108